Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study
- 1 April 1999
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (4) , 1127
- https://doi.org/10.1200/jco.1999.17.4.1127
Abstract
PURPOSE: Patients with metastatic breast cancer, especially those with progression after several prior chemotherapy treatments, need efficient chemotherapy. This study investigates the efficacy and toxicity of docetaxel in metastatic breast cancer patients with previous chemotherapy for metastatic disease. PATIENTS AND METHODS: Thirty-one women (median age, 52 years; range, 40 to 65 years) treated for metastatic breast cancer with docetaxel were included. Eleven patients had one metastatic site, 10 patients had two, and 10 patients had three or more. The planned dose of docetaxel per course was the standard treatment of 100 mg/m2 (or 75 mg/m2 if liver enzyme levels were abnormal) every 3 weeks, given for six or eight cycles. RESULTS: The overall response rate was 48% (three complete responses [CR] and 11 partial responses [PR] ), and the median duration of response was 7 months (range, 2 to 16 months). Twenty patients (65%) experienced fatigue, and 27 patients (87%) had alopecia. Fifteen cases (48%) of grade 4 leukopenia were observed. Edema with a weight gain of 2 to 15 kg was seen in 12 patients (39%), and mucositis occurred in 20 patients (65%). Twenty-three patients (74%) interrupted treatment before reaching the planned number of courses, nine patients owing to progression of cancer and 14 owing to toxicity. Dose reduction was required in 18 (61%) of the patients. Only two patients were able to receive the planned eight courses without dose reduction. CONCLUSION: Docetaxel is highly active in metastatic breast cancer, even as a third-line treatment, and can be considered as an efficient standard option in second-line treatment. The standard recommended dose level of 100 mg/m2 is not feasible in heavily pretreated patients; therefore, for such patients, an initial dose level not exceeding 75 mg/m2 is recommended.Keywords
This publication has 12 references indexed in Scilit:
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Docetaxel: response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancerEuropean Journal Of Cancer, 1998
- Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.Journal of Clinical Oncology, 1998
- Review of recent trials of chemotherapy for advanced breast cancer: the taxanesEuropean Journal Of Cancer, 1997
- First-line treatment of metastatic breast cancerAnti-Cancer Drugs, 1996
- A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerBritish Journal of Cancer, 1996
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995
- A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancerAnnals of Oncology, 1994
- Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators on Node-Negative Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1993
- Systemic Therapy of Advanced Breast CancerDrugs, 1992